Business
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment. The Company is actively seeking to collaborate with several renowned clinical researchers and top global cognitive institutes for studies evaluating the effectiveness of SofPulse® in treating TBI patients. The studies will assess the efficacy of SofPulse® to reduce symptoms of TBI resulting from acute head injuries such as concussions and Post-Concussion Syndrome (PCS), including headaches, dizziness and cognitive impairment. Reaction from TBI Researchers Endonovo has received an overwhelmingly positive response from clinical researchers regarding the potential effectiveness of its SofPulse® Pulsed Electro Magnetic Field (PEMF) technology in treating TBI. SofPulse® has garnered significant interest from neuroscientists, orthopedic neurologists and cognitive researchers at some of the most prestigious institutions in the world, including Harvard University, Boston’s Spaulding Rehabilitation Hospital and Stanford University. \"CNS (Central Nervous Symptom), TBI and PCS are some of the most challenging healthcare issues that we face today,” according to Ira Weisberg, Endonovo Medical Division President. Additionally, Weisberg stated: “With our SofPulse® PEMF technology, we have the potential to revolutionize the way we approach and treat these problems. We are committed to collaborating with the best and brightest minds in TBI research to develop groundbreaking therapies that will prove the effectiveness of our technology in treating these conditions. We believe that the potential impact of our SofPulse® technology on the healthcare industry cannot be overstated, and we are excited to be at the forefront of this groundbreaking research.\" Collaboration with top TBI researchers highlights Endonovo’s continued commitment in the TBI treatment landscape as it seeks to develop medical technologies to enhance patient outcomes for the treatment of TBI. Development of new studies evaluating TBI treatments should pave the way for the expansion of the Company's research platform for the further development of its patented PE...